## HIGHLIGHTS

521 Selected Articles from This Issue

## SPECIAL FEATURES

### CCR Translations

523 Metformin in Gynecologic Cancers: Opening a New Window for Prevention and Treatment?
Ainhoa Madariaga, Pamela J. Goodwin, and Amit M. Oza
See related articles, p. 581 and p. 632

526 Metastatic Breast Cancer: TIL it is Too Late
Peter Savas and Sherene Loi
See related article, p. 637

529 Building on the Promise of Cancer Vaccines for Solid Tumors
Craig L. Slingluff Jr
See related article, p. 588

### CCR Drug Updates

532 FDA Approval Summary: Tagraxofusp-erzs For Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
Emily Y. Jen, Xin Gao, Liang Li, Luning Zhuang, Natalie E. Simpson, Baikuntha Aryal, Rong Wang, Donna Przepiorka, Yuan Li Shen, Ruby Leong, Chao Liu, Christopher M. Sheth, Steven Bowen, Kirsten B. Goldberg, Ann T. Farrell, Gideon M. Blumenthal, and Richard Pazdur

### Review

537 Mutated RAS: Targeting the "Untargetable" with T Cells
Praveen D. Chatani and James C. Yang

## Perspectives

545 Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade

## CLINICAL TRIALS: TARGETED THERAPY

552 Everolimus and Octreotide for Patients with Recurrent Meningiomas: Results from the Phase II CEVOREM Trial
Thomas Graillon, Marc Sanson, Chantal Campello, Ahmed Idbaih, Matthieu Peyre, Hadrien Peyrière, Noémie Basset, Didier Autran, Catherine Roche, Michel Kalamarides, Pierre-Hugues Roche, Stéphane Fuentes, Emeline Tabouret, Maryline Barrie, Anita Cohen, Stéphane Honoré, Mohamed Boucekeine, Karine Baumstarck, Dominique Figarella-Branger, Anne Barlier, Henry Dufour, and Olivier Louis Chinot

558 Pilot Trial AMC-063: Safety and Efficacy of Bortezomib in AIDS-associated Kaposi Sarcoma

566 Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR- /HER2- Breast Cancer
Sara A. Hurvitz, Miguel Martin, Michael F. Press, David Chan, Maria Fernandez-Abad, Edgar Petru, Regan Rostorf, Valentina Guarneri, Chiun-Sheng Huang, Susana Barriga, Sameera Wijayawardana, Manisha Brahmachary, Philip J. Ebert, Anwar Hossain, Jiangang Liu, Adam Abel, Amit Aggarwal, Valerie M. Jansen, and Dennis J. Slamon
TABLE OF CONTENTS

581 Everolimus, Letrozole, and Metformin in Women with Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-Center, Single Arm, Phase II Study
See related commentary, p. 523

CLINICAL TRIALS: IMMUNOTHERAPY

588 A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors
See related commentary, p. 529

598 Intratumoral Delivery of Plasmid IL12 Via Electroporation Leads to Regression of Injected and Noninjected Tumors in Merkel Cell Carcinoma

PRECISION MEDICINE AND IMAGING

608 Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance

623 Validation of the OncoMasTR Risk Score in Estrogen Receptor–Positive/HER2-Negative Patients: A TransATAC study

TRANSLATIONAL CANCER MEchanisms AND therapy

632 Metformin Abrogates Age-Associated Ovarian Fibrosis
See related commentary, p. 523

643 The Outcome of TGFβ Antagonism in Metastatic Breast Cancer Models In Vivo Reflects a Complex Balance between Tumor-Suppressive and Proprogression Activities of TGFβ

657 Comprehensive Profiling of Poor-Risk Paired Primary and Recurrent Triple-Negative Breast Cancers Reveals Immune Phenotype Shifts
Katherine E. Hutchinson, Susan E. Yost, Ching-Wei Chang, Radia Marie Johnson, Adrian R. Carr, Paul R. McAdam, Daniel L. Halligan, Chun-Chieh Chang, Daniel Schmolze, Jackson Liang, and Yuan Yuan
See related commentary, p. 526

669 EGFL7 Antagonizes NOTCH Signaling and Represents a Novel Therapeutic Target in Acute Myeloid Leukemia
Marius Bill, Aparna Pathamathan, Malith Karunasiri, Changxian Shen, Matthew H. Burke, Parvati Ranganathan, Dimitrios Papaioannou, Nina C. Zitzer, Katiri Snyder, Allison LaRocco, Allison E. Walker, Zachary J. Brannan, Ansel P. Nalin, Aharon G. Freud, Mikhail M. Dikov, Xiaoli Zhang, Clara D. Bloomfield, Ramiro Garzon, and Adrienne M. Dorrance

679 Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen-Specific T Cells
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>690</td>
<td>Colony-Stimulating Factor 1 Receptor (CSF1R) Activates AKT/mTOR Signaling and Promotes T-Cell Lymphoma Viability</td>
</tr>
<tr>
<td>690</td>
<td>Carlos Murga-Zamalloa, Delphine C.M. Rolland, Avery Polk, Ashley Wolfe, Hiran Dewar, Pinki Chowdhury, Ozlem Onder, Rajan Dewar, Noah A. Brown, Nathanael G. Bailey, Kedar Inamdar, Megan S. Lim, Kojo S.J. Elenitoba-Johnson, and Ryan A. Wilcox</td>
</tr>
<tr>
<td>704</td>
<td>Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy</td>
</tr>
<tr>
<td>704</td>
<td>Kristin C. Hicks, Karin M. Knudson, Karin L. Lee, Duane H. Hamilton, James W. Hodge, William D. Figg, Peter Ordentlich, Frank R. Jones, Shahrooz Rabizadeh, Patrick Soon-Shiong, Jeffrey Schlom, and Sofia R. Gameiro</td>
</tr>
<tr>
<td>717</td>
<td>Impact of Prior Bevacizumab Treatment on VEGF-A and PlGF Levels and Outcome Following Second-Line Aflibercept Treatment: Biomarker Post Hoc Analysis of the VELOUR Trial</td>
</tr>
<tr>
<td>717</td>
<td>Eric Van Cutsem, Caroline Paccard, Marielle Chiron, and Josep Tabernero</td>
</tr>
<tr>
<td>726</td>
<td>Comprehensive Transcriptome Profiling of Cryptic CBFA2T3–GLIS2 Fusion–Positive AML Defines Novel Therapeutic Options: A COG and TARGET Pediatric AML Study</td>
</tr>
<tr>
<td>738</td>
<td>Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy</td>
</tr>
<tr>
<td>738</td>
<td>Carmine De Angelis, Chandandeep Nagi, Cliff C. Hoyt, Linying Liu, Kristin Roman, Chichung Wang, Yi Zheng, Jamunarani Veeraraghavan, Vidyalakshmi Sethunath, Paolo Nuciforo, Tao Wang, Anna Tsimelzon, Sufeng Mao, Susan G. Hilsenbeck, Meghan V. Trivedi, Maria Letizia Cataldo, Anne Pavlick, Antonio C. Wolff, Britta Weigel, Jorge S. Reis-Filho, Alex Prat, Carolina Gutierrez, Charles Kent Osborne, Mothaffar F. Rimawi, and Rachel Schiff</td>
</tr>
<tr>
<td>746</td>
<td>MAP9 Loss Triggers Chromosomal Instability, Initiates Colorectal Tumorigenesis, and Is Associated with Poor Survival of Patients with Colorectal Cancer</td>
</tr>
<tr>
<td>746</td>
<td>Shiyan Wang, Junzhe Huang, Chuangen Li, Luyang Zhao, Chi Chun Wong, Jianming Zhai, Yunfei Zhou, Wen Deng, Yong Zeng, Shanzhan Gao, Yanquan Zhang, Guoping Wang, Xin Yuan Guan, Hong Wei, Sunny H. Wong, Housheng H. He, Jerry W. Shay, and Jun Yu</td>
</tr>
<tr>
<td>758</td>
<td>Correction: Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy</td>
</tr>
<tr>
<td>758</td>
<td>Carmela Passaro, Quazim Alayo, Isabel DeLaura, John McNulty, Korneel Grauwet, Hirotaka Ito, Vivek Bhaskaran, Marco Mineo, Sean E. Lawler, Khalid Shah, Maria C. Speranza, William Goins, Eric McLaughlin, Soledad Fernandez, David A. Reardon, Gordon J. Freeman, E. Antonio Chiocca, and Hiroshi Nakashima</td>
</tr>
</tbody>
</table>

AC icon indicates AuthorChoice
For more information please visit www.aacrjournals.org
ABOUT THE COVER

The cover shows increased intratumoral CD8 T-cell infiltration, accompanied by PD-1 and PD-L1 expression and loss of tumor cells, in a previously "cold" Merkel cell carcinoma (MCC) metastasis after intratumoral injection of interleukin-12 plasmid (tavo) followed by in vivo electroporation (EP). Resultant local inflammation from i.t.-tavo-EP led to systemic immune responses, with regression of noninjected MCC lesions in several patients. For details, see article by Bhatia et al on page 598 of this issue.